OmniAb, Inc. SEC Filings

OmniAb, Inc. (OABI) – Form 4 filed 18-Jun-2025

Director Steven Love reported several equity transactions dated 17-Jun-2025. The filing shows a routine mix of RSU vesting, fresh equity grants and the associated increase in directly held common shares.

• RSU vesting (Code M): 20,000 previously awarded restricted stock units converted into an equal number of common shares. Mr. Love’s direct shareholdings rose to 58,333 shares following the conversion.
• New RSU grant (Code A): 20,000 RSUs were awarded. These units vest in full on the earlier of OmniAb’s next annual shareholder meeting or the first anniversary of the grant date.
• New stock option grant (Code A): 40,000 options with a strike price of $1.70 and a 10-year term (expiring 17-Jun-2035) were issued. The option vests in full on the same schedule as the RSUs.

Post-transaction derivative holdings now comprise 46,667 RSUs and 40,000 stock options, while non-derivative ownership stands at 58,333 common shares. No open-market sales were disclosed, indicating that all changes stem from equity compensation and not from dispositions that might pressure the share float.

Because the reported activities involve standard director compensation and do not reflect purchases or sales on the open market, the filing is generally viewed as neutral-to-slightly-positive: it aligns the director’s incentives with shareholders without signaling divestiture. Material financial performance data is not included in this filing.

OmniAb, Inc. (OABI) – Form 4 insider activity dated 06/17/2025

Director John L. Higgins reported multiple equity transactions. He converted 20,000 previously granted RSUs (transaction code M), receiving an equal number of common shares at no cash cost and lifting his directly held stake to 2,851,887 shares. No shares were sold.

On the same day, the board granted Higgins a new equity package comprising 20,000 RSUs and 40,000 stock options with a $1.70 exercise price expiring 06/17/2035. Both awards vest in full on the earlier of the next annual shareholder meeting or 12 months from grant, aligning with the company’s typical director compensation schedule.

Post-transactions, Higgins’ derivative exposure consists of 33,172 unvested RSUs and 40,000 unexercised options. The filing signals continued long-term alignment as the insider’s net ownership increased and no dispositions were made. The incremental dilution from the new awards is de minimis relative to OmniAb’s outstanding share count and does not alter the firm’s capital structure.

Form 4 filing for OmniAb, Inc. (OABI) dated 18-Jun-2025 discloses equity transactions by director Carolyn R. Bertozzi on 17-Jun-2025.

• Common stock: 20,000 shares were acquired upon vesting of previously granted restricted stock units (RSUs). Post-transaction direct ownership stands at 75,539 shares.
• New equity grants: (i) 20,000 RSUs, each convertible into one common share, and (ii) a stock option for 40,000 shares with a $1.70 exercise price and 17-Jun-2035 expiration. All new awards vest in full on the earlier of the next annual shareholder meeting or the first anniversary of the 17-Jun-2025 grant date.
• No dispositions of shares occurred; all reported transactions increase or maintain the insider’s exposure to OmniAb’s equity.

These routine director equity awards and vesting events align incentives with shareholders and do not, by themselves, alter OmniAb’s fundamentals. The filing satisfies Section 16 reporting obligations and contains no indications of sales, pledges, or derivative hedging.

Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) is offering $250,000 of Autocallable Contingent Coupon Equity-Linked Securities tied to the common stock of Alnylam Pharmaceuticals, Inc. (ALNY). The notes are part of the issuer’s Medium-Term Senior Notes, Series N, and are offered under a 424(b)(2) prospectus supplement.

Economics

• Denomination: $1,000 per security.
• Issue price: $1,000; estimated value on the pricing date: $964.60 (reflects distribution/hedging costs and internal funding rate).
• Underwriting fee: up to $20 (2.0%) per note; net proceeds to issuer: $980.
• Initial underlying value (ALNY close 30-Jun-2025): $326.09.

Coupon mechanics

• Quarterly contingent coupon of 3.00% of par (12.00% p.a.) paid only if ALNY’s closing price on the relevant valuation date is ≥ the coupon barrier of $195.654 (60 % of initial value).
• If the barrier is breached, that coupon period pays $0; missed coupons are not recaptured.

Autocall feature

• On each valuation date from 30-Sep-2025 to 30-Mar-2028, the notes autocall at par (plus coupon) if ALNY ≥ initial value. Early redemption shortens the maximum coupon horizon.

Principal repayment at maturity (6-Jul-2028)

• If not previously called and final ALNY price ≥ final barrier of $195.654 (60 % of initial): receive par plus final coupon.
• If final price < barrier: receive $1,000 × (1 + underlying return), exposing investors to full downside, potentially zero.

Risk profile

• No principal protection; up to 100 % loss possible.
• High probability of missed coupons if ALNY stays below the 60 % threshold.
• Credit exposure to Citigroup Global Markets Holdings Inc. and guarantor Citigroup Inc.
• No listing; secondary market liquidity depends solely on CGMI.
• Tax treatment uncertain; issuer intends to treat coupons as ordinary income.

Key dates: Pricing 30-Jun-2025; Issue 3-Jul-2025; first valuation/autocall 30-Sep-2025; maturity 6-Jul-2028.

The product targets investors seeking enhanced income versus conventional Citi debt but who can tolerate equity risk in a single biotech name, potential illiquidity, and complex tax treatment.